Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGE AgeX Therapeutics		$4.54	$11.07 ▼ $35.71	$11.99M	1.18	3,849 shs	3,700 shs
CTMX CytomX Therapeutics	$2.25 -2.6%	$1.90	$0.40 ▼ $3.10	$181.40M	2.09	2.18 million shs	2.54 million shs
FBRX Forte Biosciences	$12.25 +7.4%	$9.21	$4.11 ▼ $28.68	$80.61M	2.85	170,923 shs	352,690 shs
IMMX Immix Biopharma	$2.17 -3.1%	$2.14	$1.26 ▼ $3.00	$60.50M	0.31	153,360 shs	170,910 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGE AgeX Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CTMX CytomX Therapeutics	0.00%	-3.02%	-10.71%	+253.88%	+84.43%
FBRX Forte Biosciences	0.00%	-16.44%	+45.83%	+57.86%	+56,929.80%
IMMX Immix Biopharma	0.00%	-3.13%	-6.87%	+29.17%	+9.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	4.2728 of 5 stars	3.5	1.0	0.0	4.7	2.9	1.7	1.3
FBRX Forte Biosciences	3.0423 of 5 stars	3.5	4.0	0.0	0.0	2.5	1.7	0.6
IMMX Immix Biopharma	3.7346 of 5 stars	3.5	5.0	0.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGE AgeX Therapeutics	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	137.04% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	397.96% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	222.58% Upside

Current Analyst Ratings Breakdown

Latest AGE, CTMX, FBRX, and IMMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/1/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $61.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGE AgeX Therapeutics	$140K	0.00	N/A	N/A	($16.07) per share	0.00
CTMX CytomX Therapeutics	$138.10M	1.31	$0.36 per share	6.22	($0.01) per share	-225.00
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGE AgeX Therapeutics	-$14.80M	-$13.03	N/A	N/A	N/A	-10,424.65%	N/A	-120.90%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.48	4.69	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)

Latest AGE, CTMX, FBRX, and IMMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGE AgeX Therapeutics	N/A	0.13	0.36
CTMX CytomX Therapeutics	N/A	1.73	1.73
FBRX Forte Biosciences	N/A	5.22	5.22
IMMX Immix Biopharma	N/A	1.80	1.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGE AgeX Therapeutics	12.50%
CTMX CytomX Therapeutics	67.77%
FBRX Forte Biosciences	77.63%
IMMX Immix Biopharma	11.26%

Insider Ownership

Company	Insider Ownership
AGE AgeX Therapeutics	6.50%
CTMX CytomX Therapeutics	6.60%
FBRX Forte Biosciences	5.90%
IMMX Immix Biopharma	55.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGE AgeX Therapeutics	5	1.08 million	1.01 million	Not Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable

AGE, CTMX, FBRX, and IMMX Headlines

Recent News About These Companies

Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen

June 27 at 12:30 AM | marketbeat.com

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 35.6% in May

June 17, 2025 | marketbeat.com

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

June 6, 2025 | zacks.com

Immix Biopharma Attends FDA CEO Forum in Washington DC

June 6, 2025 | globenewswire.com

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

June 6, 2025 | msn.com

HC Wainwright Predicts Stronger Earnings for Immix Biopharma

June 6, 2025 | marketbeat.com

Brokers Issue Forecasts for Immix Biopharma Q1 Earnings

June 5, 2025 | marketbeat.com

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025

June 5, 2025 | nasdaq.com

Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial

June 4, 2025 | msn.com

Immix Biopharma (NASDAQ:IMMX) Receives "Buy" Rating from HC Wainwright

June 4, 2025 | marketbeat.com

Immix Biopharma Enters At The Market Offering Agreement

June 3, 2025 | tipranks.com

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

June 3, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/03/3093133/0/en/immix-biopharma-announces-primary-endpoint-met-in-positive-nxc-201-interim-results-presented-at-asco-enabling-path-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis.html$

Immix Biopharma Inc.

May 27, 2025 | wsj.com

Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis

May 24, 2025 | nasdaq.com

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/23/3087484/0/en/immix-biopharma-further-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-nexicart-2.html$

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/22/3087082/0/en/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-enabling-pathway-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis.html$

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/05/21/3086145/0/en/immix-biopharma-to-host-kol-event-to-discuss-nxc-201-clinical-data-presented-at-asco-2025-in-relapsed-refractory-al-amyloidosis.html$

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

May 19, 2025 | finance.yahoo.com

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

April 23, 2025 | globenewswire.com

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright

February 11, 2025 | msn.com

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

February 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
3 Growth Stocks Too Small for Institutions to Buy
By Gabriel Osorio-Mazilli | June 19, 2025
View 3 Growth Stocks Too Small for Institutions to Buy
ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern

AGE, CTMX, FBRX, and IMMX Company Descriptions

AgeX Therapeutics NYSE:AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

CytomX Therapeutics NASDAQ:CTMX

$2.25 -0.06 (-2.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.29 +0.04 (+1.82%)

As of 05:05 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Forte Biosciences NASDAQ:FBRX

$12.25 +0.84 (+7.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.00 -2.25 (-18.38%)

As of 04:03 AM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Immix Biopharma NASDAQ:IMMX

$2.17 -0.07 (-3.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.09 (-4.15%)

As of 04:00 AM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time